Most side effects resolve within 23 weeks as your body adapts, and dose escalation is carefully paced to minimize tolerability issues
These processes are central to the pathogenesis of a wide range of NDDs, including Alzheimers disease (AD), Parkinsons disease (PD), primary tauopathies (e.g., progressive supranuclear palsy [PSP], corticobasal degeneration [CBD], tau-linked frontotemporal dementia [FTD-tau]), frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), synucleinopathies (e.g., Lewy body dementia [LBD] and multiple system atrophy [MSA]), Huntingtons disease (HD) and related polyglutamine (polyQ) diseases (e.g., spinocerebellar ataxias [SCA]), and prion diseases (PrD)
Store reconstituted peptides at 2-8C (refrigerated) protected from light
Finally, while these ingredients are generally recognized as safe and well-tolerated, they are powerful biochemical modulators